Longevity · Mitochondrial coenzyme · Compounded 503A
NAD+: the coenzyme your mitochondria run on.
NAD+ (nicotinamide adenine dinucleotide) is the coenzyme every cell uses to generate energy and repair DNA. Levels fall measurably with age. Restoring NAD+ — through direct infusion, injection, or precursors like NMN and NR — is one of the most studied longevity interventions of the last decade.
What NAD+ is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It shuttles electrons through the mitochondrial electron transport chain to generate ATP — the energy currency of the body — and serves as the obligatory substrate for sirtuins (the SIRT1–SIRT7 family), PARP DNA-repair enzymes, and CD38.
Tissue NAD+ levels decline meaningfully with age. Human studies have measured 40–60% drops in skin and skeletal-muscle NAD+ between the third and seventh decades of life. The decline correlates with mitochondrial dysfunction, reduced DNA repair capacity, and many of the hallmarks of aging described by López-Otín and colleagues.
Therapeutic NAD+ is delivered three ways: as NAD+ itself (subcutaneous injection or IV infusion), or as the precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), which the body converts intracellularly. kindr's longevity physicians evaluate which route fits a given patient.
How it works
NAD+ has two principal roles. First, it accepts electrons during glycolysis and the TCA cycle (becoming NADH), which feeds the mitochondrial electron transport chain and produces ATP. Without enough NAD+, mitochondrial energy output drops and cells switch toward less efficient glycolysis.
Second, NAD+ is consumed (not recycled) by sirtuins, PARPs, and CD38. Sirtuins deacetylate histones and metabolic enzymes — turning on stress-resistance and longevity programs. PARPs use NAD+ to repair single-strand DNA breaks. CD38 activity rises with age and depletes NAD+, which is one mechanism behind age-related NAD+ loss.
Restoring NAD+ pools re-enables sirtuin and PARP function. In animal models this translates to improved mitochondrial function, better glucose tolerance, restored exercise capacity in aged mice, and improved vascular function. Human evidence is still developing but consistent for safety and pharmacokinetics of NMN and NR.
What patients use it for
Mitochondrial energy
By replenishing the NAD+ pool, cells maintain electron-transport-chain throughput. Patients commonly report improved sustained energy within 1–3 weeks of starting therapy.
DNA repair capacity
PARP-1 requires NAD+ to repair the thousands of single-strand DNA breaks every cell sustains per day. Adequate NAD+ supports genomic stability — particularly relevant after age 50.
Sirtuin activation
SIRT1 and SIRT3 govern metabolic flexibility, autophagy, and stress resistance. Both are NAD+-dependent. Restoring NAD+ enables these longevity-associated pathways.
Cognitive clarity
The brain is metabolically expensive — roughly 20% of resting energy expenditure. Several pilot studies report improved subjective clarity and focus with NAD+ protocols, though larger trials are needed.
Metabolic flexibility
NMN supplementation in postmenopausal women with prediabetes improved muscle insulin sensitivity in a 2021 Washington University trial — the first rigorous human evidence for a metabolic benefit.
Evidence summary
Human evidence for NAD+ precursors (NMN and NR) is now well-established for safety, tolerability, and the ability to raise blood and tissue NAD+ levels. The 2021 Yoshino et al. trial at Washington University demonstrated improved muscle insulin sensitivity in postmenopausal women given oral NMN.
NR has multiple human pharmacokinetic and safety trials at doses of 250–1000 mg daily showing dose-dependent NAD+ elevation in whole blood. Long-term outcome trials are ongoing.
Direct NAD+ injection and IV infusion are widely used clinically but the rigorous outcome evidence base is smaller than for the oral precursors. Physician supervision and individualized dosing matter.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Subcutaneous NAD+ is typically dosed 100–250 mg per injection, 1–3 times per week, often as a 4–8 week loading protocol followed by maintenance.
IV NAD+ infusions range from 250 mg to 1000+ mg per infusion, scheduled weekly or monthly. Initial infusions are administered slowly to minimize chest pressure and GI sensations — common, transient, dose-dependent.
NMN and NR are dosed orally at 250–1000 mg daily. Many longevity protocols combine an oral precursor for daily NAD+ support with periodic NAD+ injections for upstream pool restoration. Your kindr physician will design the regimen.
Safety and contraindications
NAD+ has a wide safety margin in healthy adults. The most common side effects of infusion are chest tightness, flushing, and nausea — all rate-dependent and resolving when the infusion is slowed.
Not recommended in pregnancy or breastfeeding. Caution in active cancer (sirtuin and PARP effects on tumor biology are an active research area). Patients with CKD, severe liver disease, or active autoimmune disease are evaluated case-by-case.
Compounded NAD+ for injection or infusion is prepared by licensed 503A pharmacies. It is not an FDA-approved drug product for any indication. Off-label use under physician supervision only.
Who it's typically considered for
- Women in perimenopause or menopause noticing energy decline, recovery loss, or cognitive fog
- Adults with measurably reduced exercise capacity or mitochondrial-axis lab findings
- Patients already on HRT or peptide protocols who want a longevity-axis layer
- Anyone interested in evidence-based mitochondrial support under medical supervision
Frequently asked questions
Is NAD+ a peptide?
Technically, no. NAD+ is a dinucleotide coenzyme — two nucleotides joined by phosphate groups. It is included in the kindr longevity catalog because it is administered through the same injectable / infusion pathway and prescribed alongside many of the peptides for the same outcomes (energy, recovery, cellular health).
NAD+ vs NMN vs NR — what is the difference?
NAD+ is the active molecule. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors the body converts to NAD+. Oral precursors are convenient for daily use; injections and infusions raise pools more directly. The right choice depends on goals, budget, and labs.
How fast will I feel something?
Subjective energy and clarity often shift within 1–3 weeks of consistent NAD+ therapy. Sleep and recovery benefits may follow at 4–8 weeks. Longevity-axis benefits (mitochondrial markers, insulin sensitivity, fat oxidation) are measured at 3–6 months.
Are IV NAD+ infusions worth the time?
For some patients, yes — particularly when faster pool restoration is needed or when oral precursors have plateaued. IV is more costly and time-intensive. For maintenance, subcutaneous injection or oral precursor is usually sufficient.
Can I take NAD+ with HRT?
Yes. NAD+ and hormone replacement therapy address different systems and are commonly layered. Your kindr physician reviews your full regimen before adding NAD+.
Is NAD+ safe for women in menopause?
For healthy women in perimenopause and menopause with no contraindications, NAD+ is well-tolerated. The 2021 NMN trial in postmenopausal women is the strongest signal that the NAD+ axis is therapeutically relevant for this population.
How much does NAD+ therapy cost through kindr?
The initial physician review is free. Compounded NAD+ for subcutaneous injection typically runs $150–$300 per month. IV protocols are priced separately. A transparent quote is provided before any prescription is filled.
Is NAD+ FDA-approved?
No. NAD+ for IV infusion or subcutaneous injection is not FDA-approved. It is prepared by licensed 503A compounding pharmacies under physician prescription for off-label use.
Sources
- Yoshino M et al. NMN increases muscle insulin sensitivity in prediabetic women. Science (2021). — www.science.org/doi/10.1126/science.abe9985
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules. Cell Metabolism (2018). — www.ncbi.nlm.nih.gov/pmc/articles/PMC6342515
- Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE (2012). — journals.plos.org/plosone/article?id=10.1371/journal.pone.0042357
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications (2018). — www.nature.com/articles/s41467-018-03421-7
- López-Otín C et al. The hallmarks of aging. Cell (2013, updated 2023). — www.cell.com/cell/fulltext/S0092-8674(13)00645-4
Considering NAD+?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.